Some genes that targets co-occurred with, such as BRAF, PDGFRB, APC, IGF1R, and MTOR, have been targeted by drugs to treat tumor progression (Wang et al., 2014; Kavuri et al., 2015; Long et al., 2015; Smyth et al., 2016; David et al., 2017; Zhang et al., 2018; Sullivan et al., 2019). This evidence concerns the gene PDGFRB and neoplasm.